Stefan Yee

chairman and non – executive director

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance.

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking and private equity with companies as KPMG, Linklaters, the Flemish investment bank Lessius, the Belgian Corporation for International Investment (SBI/BMI), Beluga (Euronext Brussels) and as the founder and CEO of the PE Group, a Belgian privately held private equity firm. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI, The Reference, Alro Holdings, Loomans Group, United Brands, Capco, Faseas International (Spacewell), HD Partners (Dekabo group), AED Rent, UnifiedPost Group, NRG New Generation, Axiles Bionics, including several healthcare companies (Docpharma (formerly Euronext Brussels), Uteron Pharma and Imcyse). Stefan holds Masters degrees in Law and Business Management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago (as a BAEF Fellow).

Leon Van Rompay

non – executive director

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in.

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee.

Marc Foidart

independent director

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL.

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL, Member of the Executive Committee of Noshaq SA in charge of the Life Sciences sector, CEO of B2H SA, the public company superseding the Liege life sciences ecosystem, and Investment Manager of Epimede SA, a EUR 50 million Belgian based private high-tech growth fund. He has more than 15 years of experience in strategic consulting and investment at all stages of development of small and medium high tech- high growth life sciences enterprises. He played a key role in several financing rounds at critical development stages of various Belgian young biotech companies among which: Mithra Pharmaceuticals SA, Imcyse SA, Uteron Pharma SA, PDC Line Pharma SA, Diagenode SA. As an entrepreneur, Marc Foidart is Co-Founder and past CEO of Arlenda SA, a spin-off company of the University of Liège providing expert statistical solutions to the pharmaceutical, chemical and environment industries. He is also Co-Founder and Executive Chairman of Eyed Pharma SA, a start-up company developing innovative controlled release microimplants in ophthalmology. Marc Foidart has been associate professor at the University of Liege since 2011.

Vincent Van Dessel

independent director

Vincent started his career in 1984 as a stockbroker at Cohen, De Greef, Van Dessel & C° in Brussels (Belgium) and later (1989) Van Dessel & C° in Antwerp (Belgium). In 1992, he joined the Brussels Stock Exchange (which became part of Euronext in 2000) as Markets and Listing Director and became member of the managing board Brussels Stock Exchanges (1998), member of the Executive Committee of Euronext NV (2000), member of the Management Board of NYSE Euronext and Chairman and CEO of NYSE Euronext Brussels (2009) and member of the Managing Board of Euronext NV and Chairman and CEO of Euronext Brussels (2014).

He served as Chairman of the Brussels Market Authority from 2000 to 2003 and was member of the Belgian Corporate Governance Committee from 2009 till 2023 and member of the Euribor Steering Committee from 2015 till 2020.

Recently, he has been appointed member of the Board of VFB (May 2024)

He is Licenciaat-Doctorandus in Applied Economics from the KULeuven University, Belgium and has been guest lecturer in several universities including the KULeuven, UCL, Lille University, Solvay Business School, HEC Liège Antwerp University and Paris Sorbonne.

He is born on 25 November 1958 in Mechelen, Belgium, married and father of twins born in 1990.

Revital Rattenbach

independent director

Seasoned entrepreneur in biotech with 15+ years of experience, Revital Rattenbach is the founding CEO of 4P pharma, a clinical stage biotech specialized in drug regeneration for treating severe diseases.

Under her CEOship, 4P Pharma assembled a unique circular drug development platform which delivered 2 programs in clinical stage while nurturing a furnished preclinical pipeline. She signed multiple academic and pharma collaborations worldwide and closed series of fundraising since 4P incorporation 8 years ago.

Prior to her role at 4P, Revital was the Head of PharmaSeed Europe (2013-2014) a research organization specialized in early development where she supervised all BD activities, finance and operations.

Prior to PharmaSeed, Revital started her entrepreneurship path by co-founding Adstem, a spin-off of Sorbonne University to activate endogenous adult stem cells. Revital is board member of Biosenic, listed company on Euronext Brussels and she holds a PhD in Biology from University of Paris VI and an MBA from Sorbonne University.

Stijn Van Rompay

co-chief executive officer & co-founder

Mr. Stijn Van Rompay has over 20 years of experience in leadership positions at various pharmaceutical companies.

Stijn co-founded and was the CEO of Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen

co-chief executive officer, chief business development officer & co-founder

Mr. Thomas Jacobsen has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development.

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.

Jean-Luc Vandebroek

Chief Financial Officer

Jean-Luc Vandebroek is a seasoned executive who joined us in September 2021 from his role as CFO of Bone Therapeutics, a publicly traded biotech company based in Gosselies, Belgium. Prior to that, he was CFO and CIO at Alcopa and Fluxys, and before that, he held various senior financial positions at Delhaize Group. Jean-Luc is an experienced Executive Board member and has a track record of developing and implementing financing strategies and transactions and has a large, global network of investors and financial institutions. Jean-Luc holds a Master in Business Administration from the Louvain Management School.

Dietmar Aichhorn

chief operating officer

Dr. Dietmar Aichhorn, PhD, has over 20 years of experience in various scientific roles within the pharmaceutical industry.

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing all scientific affairs. Dietmar graduated as chemical engineer in Linz but has perfected his project management skills at the university of Vienna.

Koenraad Van der Elst

chief legal officer

Mr. Koenraad Van der Elst has more than 30 years of experience as an in-house and external legal and general counsellor for various listed companies.

Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.

In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.

Grow with us

We are driven to continuously innovate existing medications and offer meaningful benefits to patients, physicians and payors.

Why join us

The key to success is an exceptional workforce. Great people generate great results. As a young, entrepreneurial company, Hyloris fosters creativity, courage, and professionalism.
At Hyloris you will be part of multicultural and multidisciplinary team who will support you to further develop and grow your personal skills.

We strive to create an exciting and dynamic working environment in which you will be challenged to take initiative, contributing to the success of the company.

Interested in joining our mission to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors? Check out our vacancies below.

We look forward to hearing from you.

Latest vacancies

Project Manager

Location: Anywhere

view vacancy

We are currently looking for a Project Manager. The successful candidate will be responsible for managing, coordinating, and delivering product development programs from an early-stage development phase until filing to Health Authorities, launch and routine commercial manufacturing.

Job description

In a matrix organization, as Project Manager, you will:

  • Work together with project team members and research scientists who would take on all scientific and technical matters in experimental study designs.
  • Prepare target product profiles, project development plans and budgets.
  • Prepare and keep up-to-date project timelines and costs and provide input for financial planning.
  • Organize efficient external and internal communication (periodic calls, ad-hoc calls, check lists, work specifications).
  • Co-ordinate external and internal project responsibilities against objectives and within budget.
  • Act as an internal or external point of contact with awareness of technical milestones and timelines as well as contractual obligations.
  • Assist with the preparation of requests for proposals and project proposals.
  • Monitor progress of individual projects, anticipate and manage risks and use or develop appropriate metrics as required.
  • Prepare stage-gate reports for e.g. project strategy, progress, issues, risks, updated timelines and costs.

Your professional profile

  • Minimum Qualification: MSc or PhD in Pharmacy, Chemistry or equivalent.
  • Minimum Experience: 7 years’ experience in pharmaceutical product development and project management.
  • Languages: English (written and verbal) – French is an asset.
  • Experienced Microsoft Project software user.
  • Ability to understand commercial contracts.

Your abilities

  • Demonstrate strong work ethics, and effective written and verbal communication skills.
  • Show an organizational aptitude to be part of an outstanding team.
  • Be flexible and have a strong team player attitude with the ability to motivate and to inject energy into the project teams.
  • Have strong interpersonal skills and a collaborative and trust enabling working style for building partnerships among key stakeholders.
  • Have the adaptability, flexibility, independence and resourcefulness to both lead a big vision strategy while also willing to roll-up-sleeves and multi-task to thrive in a growing environment.
  • Show respect for individuals and cultural difference across different countries.
  • Demonstrate efficient utilization of time and resources.
  • Be proactive and result-oriented with a focus on business.
  • Can steer external partners.

About Our Company

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 16 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Outside of its core strategic focus, the Company also has 3 high barrier generic products in development and registration phase. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

Our values

Our talented staff work in accordance with our company values:

  • We are proud of our entrepreneurial culture and foster open communication, mutual respect, professionalism and efficient decision-making and we believe that our multicultural organisation is one of our most important competitive advantage.
  • We believe that timely and well considered decisions as a response to emerging opportunities and ideas is the key to our success.
  • We believe that the success of the company lies in the competence, dedication, and motivation of each of our employees.
  • We believe that freedom returns flexibility and empowerment returns commitment.

Motivation letter and CV can be sent to peter.mertens@hyloris.com

Download a PDF version here

 

Apply
Scientific Business Analyst

Location: Liege

view vacancy

ROLE & RESPONSIBILITIES

 

  1. Identify new opportunities and contact universities, hospitals, and other possible partners.
  2. Perform clinical-, epidemiological-, data-, and market research and assist in the preparation of business cases.
  3. Support activities for pipeline products.
  4. Support Management in day-to-day business-related tasks.

 

MAIN TASKS

 

  1. Proactively identify and source new opportunities.
    1. Perform market analysis using various data sources as well as scientific literature in identifying or evaluating new opportunities.
    2. Contact universities, hospitals, patent holders, Key Opinion Leaders (KOL’s), and other possible partners to scout for opportunities.
    3. Attend conferences, workshops, and industry meetings to network with potential partners, and stay updated on latest industry trends and developments.
  2. Evaluation of new product opportunities.
    1. Conduct thorough research to understand disease areas, epidemiological data, patient populations, and evaluate feasibility, unmet need, and positioning.
    2. Proactively engage external resources such as researchers, clinicians, and KOL’s to continuously validate the evaluation and findings.
    3. Evaluate competitive landscape (approvals, pipeline drugs, patent listings, market dynamics, etc.,)
    4. Assist in IP review and in evaluating market potential, pricing, regulatory strategy, and clinical strategy.
    5. Coordinate cross-functional Due Diligence activities.
    6. Prepare and present detailed business cases and opportunity assessments for senior management and the Board, leading to informed decision-making.
    7. Ensure effective communication and information flow between business development and other departments to align strategies and goals.
  3. Support activities for pipeline products.
    1. Assist in monitoring of competitor developments, including new product launches, clinical trials, and strategic partnerships.
    2. Analyze competitor movements and market trends to anticipate potential challenges and opportunities for our product portfolio.
    3. Synthesize data into actionable insights that inform strategic planning and decision-making.
    4. Provide regular updates to senior management on the competitive landscape and potential impacts on our business strategy.

POSITION REQUIREMENTS

 

  • Minimum Qualification: Scientific degree (Life Sciences or equivalent), preferably holding a relevant PhD.
    Clinical and pharmacological understanding.
  • Minimum Experience: Entry level experience in the pharmaceutical industry. Previous experience with Market and Competition analysis is an advantage.
  • Languages: Very good English (written and oral), French and/or other languages are an asset.

 

 

ABILITIES

 

  1. Good communication skills; both oral and written.
  2. Ability to break down and translate complex information into meaningful presentations for various audiences.
  3. Ability to work in multidisciplinary teams.
  4. Excellent IT skills especially digital tools such as Excel, Power Point, and Microsoft Projects ability to adopt more advanced data analytics platforms as well as AI in the daily routine.
  5. An eye for detail and capable of managing large amounts of data and perform meaningful extrapolations.
  6. Good understanding of analytical tools (Excel pivot tables and charts etc).
  7. Eager to engage in continuous learning and process improvement environment.
  8. Proactive attitude, enjoy thinking outside-the-box and reach conclusions by creative means.
  9. Strives in a multi-cultural entrepreneurial environment, with lean structure, wearing multiple hats, dealing with unexpected situations, and changing priorities.
Apply